Literature DB >> 21081214

Vascular pharmacology of epoxyeicosatrienoic acids.

Sandra L Pfister1, Kathryn M Gauthier, William B Campbell.   

Abstract

Epoxyeicosatrienoic acids (EETs) are cytochrome P450 metabolites of arachidonic acid that are produced by the vascular endothelium in responses to various stimuli such as the agonists acetylcholine (ACH) or bradykinin or by shear stress which activates phospholipase A(2) to release arachidonic acid. EETs are important regulators of vascular tone and homeostasis. In the modulation of vascular tone, EETs function as endothelium-derived hyperpolarizing factors (EDHFs). In models of vascular inflammation, EETs attenuate inflammatory signaling pathways in both the endothelium and vascular smooth muscle. Likewise, EETs regulate blood vessel formation or angiogenesis by mechanisms that are still not completely understood. Soluble epoxide hydrolase (sEH) converts EETs to dihydroxyeicosatrienoic acids (DHETs) and this metabolism limits many of the biological actions of EETs. The recent development of inhibitors of sEH provides an emerging target for pharmacological manipulation of EETs. Additionally, EETs may initiate their biological effects by interacting with a cell surface protein that is a G protein-coupled receptor (GPCR). Since GPCRs represent a common target of most drugs, further characterization of the EET receptor and synthesis of specific EET agonists and antagonist can be used to exploit many of the beneficial effects of EETs in vascular diseases, such as hypertension and atherosclerosis. This review will focus on the current understanding of the contribution of EETs to the regulation of vascular tone, inflammation, and angiogenesis. Furthermore, the therapeutic potential of targeting the EET pathway in vascular disease will be highlighted.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21081214      PMCID: PMC3373307          DOI: 10.1016/B978-0-12-385061-4.00002-7

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  139 in total

1.  An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Authors:  John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

2.  Human coronary endothelial cells convert 14,15-EET to a biologically active chain-shortened epoxide.

Authors:  Xiang Fang; Neal L Weintraub; Christine L Oltman; Lynn L Stoll; Terry L Kaduce; Shawn Harmon; Kevin C Dellsperger; Christophe Morisseau; Bruce D Hammock; Arthur A Spector
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-08-22       Impact factor: 4.733

3.  Bradykinin-induced vasodilation of human forearm resistance vessels is primarily mediated by endothelium-dependent hyperpolarization.

Authors:  M L Honing; P Smits; P J Morrison; T J Rabelink
Journal:  Hypertension       Date:  2000-06       Impact factor: 10.190

4.  Nitric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo.

Authors:  Y Nishikawa; D W Stepp; W M Chilian
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-08       Impact factor: 4.733

5.  Determination of EETs using microbore liquid chromatography with fluorescence detection.

Authors:  K Nithipatikom; P F Pratt; W B Campbell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-08       Impact factor: 4.733

Review 6.  Epoxyeicosatrienoic acid analogs and vascular function.

Authors:  V Sudhahar; S Shaw; J D Imig
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

7.  Short-term estrogen augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilation in postmenopausal women.

Authors:  H Tagawa; H Shimokawa; T Tagawa; M Kuroiwa-Matsumoto; Y Hirooka; A Takeshita
Journal:  J Cardiovasc Pharmacol       Date:  1997-10       Impact factor: 3.105

8.  5,6-epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR.

Authors:  Silvia I Pomposiello; John Quilley; Mairead A Carroll; John R Falck; John C McGiff
Journal:  Hypertension       Date:  2003-08-25       Impact factor: 10.190

9.  Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors.

Authors:  W B Campbell; D Gebremedhin; P F Pratt; D R Harder
Journal:  Circ Res       Date:  1996-03       Impact factor: 17.367

10.  Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia.

Authors:  Karni S Moshal; Darryl C Zeldin; Srinivas D Sithu; Utpal Sen; Neetu Tyagi; Munish Kumar; William M Hughes; Naira Metreveli; Dorothea S E Rosenberger; Mahavir Singh; Thomas P Vacek; Walter E Rodriguez; Adeagbo Ayotunde; Suresh C Tyagi
Journal:  J Cell Physiol       Date:  2008-06       Impact factor: 6.384

View more
  31 in total

1.  Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.

Authors:  Eric A Evangelista; Rüdiger Kaspera; Nahush A Mokadam; J P Jones; Rheem A Totah
Journal:  Drug Metab Dispos       Date:  2013-09-10       Impact factor: 3.922

2.  The biological actions of 11,12-epoxyeicosatrienoic acid in endothelial cells are specific to the R/S-enantiomer and require the G(s) protein.

Authors:  Yindi Ding; Timo Frömel; Rüdiger Popp; John R Falck; Wolf-Hagen Schunck; Ingrid Fleming
Journal:  J Pharmacol Exp Ther       Date:  2014-04-24       Impact factor: 4.030

3.  The arachidonic acid monooxygenase: from biochemical curiosity to physiological/pathophysiological significance.

Authors:  Jorge H Capdevila; John R Falck
Journal:  J Lipid Res       Date:  2018-08-28       Impact factor: 5.922

4.  Cytochrome P450 2C24: Expression, Tissue Distribution, High-Throughput Assay, and Pharmacological Inhibition.

Authors:  Jun Yang; Melissa A VanAlstine; James G Phillips; Mark P Wentland; Lindsay B Hough
Journal:  Acta Pharm Sin B       Date:  2012-04       Impact factor: 11.413

Review 5.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

Review 6.  Metabolic actions of angiotensin II and insulin: a microvascular endothelial balancing act.

Authors:  Ranganath Muniyappa; Sahzene Yavuz
Journal:  Mol Cell Endocrinol       Date:  2012-06-07       Impact factor: 4.102

Review 7.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Authors:  Arthur A Spector; Hee-Yong Kim
Journal:  Biochim Biophys Acta       Date:  2014-08-02

8.  Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase.

Authors:  In-Hae Kim; In-Hee Lee; Hisashi Nishiwaki; Bruce D Hammock; Kosuke Nishi
Journal:  Bioorg Med Chem       Date:  2014-01-03       Impact factor: 3.641

9.  5,14-HEDGE, a 20-HETE mimetic, reverses hypotension and improves survival in a rodent model of septic shock: contribution of soluble epoxide hydrolase, CYP2C23, MEK1/ERK1/2/IKKβ/IκB-α/NF-κB pathway, and proinflammatory cytokine formation.

Authors:  Bahar Tunctan; Belma Korkmaz; Ayse Nihal Sari; Meltem Kacan; Demet Unsal; Mehmet Sami Serin; C Kemal Buharalioglu; Seyhan Sahan-Firat; Tuba Cuez; Wolf-Hagen Schunck; John R Falck; Kafait U Malik
Journal:  Prostaglandins Other Lipid Mediat       Date:  2013-02-27       Impact factor: 3.072

Review 10.  Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function.

Authors:  J D Imig
Journal:  Adv Pharmacol       Date:  2016-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.